KALA BIO SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 12, 2026, 4:25 p.m. ETView on SEC.gov Our explainer
Material modification of security holders' rights · Amendments to articles or bylaws; fiscal year change · Other events · Financial statements and exhibits
AI summary, unreviewedKALA BIO Announces 1-for-30 Reverse Stock Split Effective November 13, 2026, Trading Split-Adjusted from November 16
8-KNov. 9, 2026, 9:01 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedKALA BIO Reports Preliminary Q3 2026 Net Loss of Approximately $0.8 Million, Down From $7.6 Million a Year Earlier
8-KNov. 3, 2026, 4:11 p.m. ETView on SEC.gov
Submission of matters to a vote of security holders
AI summary, unreviewedKALA BIO shareholders approve reverse stock split authority of 1-for-2 to 1-for-300 at annual meeting
SCHEDULE 13GOct. 19, 2026, 9:09 a.m. ETView on SEC.gov
8-KSept. 10, 2026, 5:24 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Financial statements and exhibits
8-KSept. 9, 2026, 5:06 p.m. ETView on SEC.gov
Shareholder director nominations · Other events
8-KAug. 28, 2026, 6:45 a.m. ETView on SEC.gov
Delisting notice / failure to meet listing standard
10-QAug. 19, 2026, 4:16 p.m. ETView on SEC.gov